New drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT02393625
Summary
This study is testing the safety and initial effectiveness of combining two drugs, ceritinib and nivolumab, for adults with advanced ALK-positive non-small cell lung cancer. It aims to find the best dose and see if the combination helps shrink tumors. The trial involves 57 participants who have previously received other treatments for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital Thoracic Oncolgoy
Boston, Massachusetts, 02115, United States
-
Mayo Clinic - Arizona
Scottsdale, Arizona, 85259, United States
-
Novartis Investigative Site
Heidelberg, Victoria, 3084, Australia
-
Novartis Investigative Site
Leuven, Vlaams Brabant, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.